{"id":3778,"date":"2026-06-05T09:43:44","date_gmt":"2026-06-05T16:43:44","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3778"},"modified":"2026-06-05T09:43:46","modified_gmt":"2026-06-05T16:43:46","slug":"roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/","title":{"rendered":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"236\" height=\"213\" src=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg\" alt=\"Roche\" class=\"wp-image-2505\" style=\"object-fit:cover;width:420px;height:310px\"\/><figcaption class=\"wp-element-caption\">Roche<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Roche&#8217;s Obinutuzumab Injection (Brand Name: Gazyvaro\u00ae\/Gazyva\u00ae) has been granted priority review by the CDE for the treatment of primary membranous nephropathy (pMN)<a href=\"https:\/\/finance.eastmoney.com\/a\/202606053761906965.html\"><\/a><a href=\"https:\/\/www.zyzhan.com\/news\/detail\/99399.html\"><\/a><a href=\"http:\/\/stockonline.com\/zh-HK\/news\/us-market\/970393\"><\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In February of this year, Roche announced that the study met its primary endpoint: the proportion of patients achieving sustained complete remission after 104 weeks of obinutuzumab treatment was higher than that with tacrolimus, with a statistically significant and clinically meaningful difference. Obinutuzumab (brand names: Gazyva\u00ae in the US \/ Gazyvaro\u00ae in Europe, and Jialuohua in China) is the world&#8217;s first humanized, glycoengineered, Type II anti-CD20 monoclonal antibody. Compared with the chimeric murine-human Type I anti-CD20 antibody rituximab, its antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are enhanced by more than 35-fold.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In June 2021, the drug was approved for marketing by the NMPA in China under the brand name Jialuohua. It is indicated, in combination with chemotherapy, for the initial treatment of adult patients with previously untreated Stage II with bulky disease, Stage III, or Stage IV follicular lymphoma who have achieved at least a partial response, followed by maintenance therapy with obinutuzumab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy Gazyva\u00ae\uff08Obinutuzumab\uff09\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche&#8217;s Obinutuzumab Injection (Brand Name: Gazyvaro\u00ae\/Gazyva\u00ae) has been granted priority review by the CDE for the treatment of primary membranous nephropathy (pMN). In February of this year, Roche announced that the study met its primary endpoint: the proportion of patients achieving sustained complete remission after 104 weeks of obinutuzumab treatment was higher than that with [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3778","post","type-post","status-publish","format-standard","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China<\/title>\n<meta name=\"description\" content=\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/roche\uff1agazyva-obinutuzumab-granted-priority-review\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/roche\uff1agazyva-obinutuzumab-granted-priority-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T16:43:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T16:43:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"236\" \/>\n\t<meta property=\"og:image:height\" content=\"213\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review\",\"datePublished\":\"2026-06-05T16:43:44+00:00\",\"dateModified\":\"2026-06-05T16:43:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/roche.jpg\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/\",\"name\":\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/roche.jpg\",\"datePublished\":\"2026-06-05T16:43:44+00:00\",\"dateModified\":\"2026-06-05T16:43:46+00:00\",\"description\":\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/roche.jpg\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/roche.jpg\",\"width\":236,\"height\":213,\"caption\":\"Roche\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China","description":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/roche\uff1agazyva-obinutuzumab-granted-priority-review\/","og_locale":"en_US","og_type":"article","og_title":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China","og_description":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/roche\uff1agazyva-obinutuzumab-granted-priority-review\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-05T16:43:44+00:00","article_modified_time":"2026-06-05T16:43:46+00:00","og_image":[{"width":236,"height":213,"url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg","type":"image\/jpeg"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review","datePublished":"2026-06-05T16:43:44+00:00","dateModified":"2026-06-05T16:43:46+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#primaryimage"},"thumbnailUrl":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/","name":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#primaryimage"},"thumbnailUrl":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg","datePublished":"2026-06-05T16:43:44+00:00","dateModified":"2026-06-05T16:43:46+00:00","description":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/roche.jpg","width":236,"height":213,"caption":"Roche"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/roche%ef%bc%9agazyva-obinutuzumab-granted-priority-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Roche\uff1aGazyva\u00ae\u00a0Obinutuzumab\u00a0Granted Priority Review"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3778"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3778\/revisions"}],"predecessor-version":[{"id":3779,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3778\/revisions\/3779"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}